Skip to main content

Advertisement

SpringerLink
Log in

Effect of adjuvant lithium on thyroxine (T4) concentration after radioactive iodine therapy

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

To study the effect of adjuvant lithium on serum thyroxine (T4) concentrations in patients treated with radioactive iodine (RAI) therapy in our environment.

Methods

This was a prospective simple randomized comparative, experimental cohort study of patients with hyperthyroidism referred for RAI ablation therapy in the two main academic hospitals in Johannesburg between February 2014 and September 2015.

Results

Amongst the 163 participants in the final analysis, 75 received RAI alone and 88 received RAI with lithium. The difference in mean T4 concentrations at 3 months between the RAI-only group (17.67 pmol/l) and the RAI with lithium group (11.55 pmol/l) was significant with a small effect size (U = 2328.5, Z = −2.700, p = 0.007, r = 0.01). Significant decreases in T4 concentrations were observed as early as 1 month after RAI (p = 0.0001) in the RAI with lithium group, but in the RAI-only group, significant decreases in T4 concentrations were observed only at 3 months after RAI therapy (p = 0.000). Women and patients with Graves’ disease who received RAI with adjuvant lithium also showed significant decreases in T4 concentrations at 1 month (p = 0.002 and p = 0.003, respectively).

Conclusion

Adjuvant lithium leads to an earlier and better response to RAI therapy with lower T4 concentrations that are achieved earlier. This earlier response and decrease in T4 concentrations were noted in patients with Graves’ disease and nodular goitre, and in women with hyperthyroidism who received adjuvant lithium therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism – prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86(8):3611–7.

    CAS  PubMed  Google Scholar 

  2. Jameson JL, Weetman AP. Diseases of the thyroid gland. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 16th ed. London: McGraw Hill; 2005. p. 2104–26.

    Google Scholar 

  3. Nordyke RA, Gilbert Jr FI. Optimal Iodine-131 dose for eliminating hyperthyroidism in Graves’ disease. J Nucl Med. 1991;32:411–6.

    CAS  PubMed  Google Scholar 

  4. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid. 2004;14(7):525–30. doi:10.1089/1050725041517093.

    Article  CAS  PubMed  Google Scholar 

  5. Vijayakumar V, Ali S, Nishino T, Nusynowitz M. What influences early hypothyroidism after radioiodine treatment for Graves’ hyperthyroidism? Clin Nucl Med. 2006;31(11):688–9. doi:10.1097/01.rlu.0000242213.26839.20.

    Article  PubMed  Google Scholar 

  6. Bogazzi F, Bartalena L, Brogioni S, Scarcello G, Burelli A, Campomori A, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1999;84(2):499–503. doi:10.1210/jcem.84.2.5446.

    CAS  PubMed  Google Scholar 

  7. Lee SL. Radioactive iodine therapy. Curr Opin Endocrinol Diabetes Obes. 2012;19(5):420–8. doi:10.1097/MED.0b013e328357fa0c.

    Article  CAS  PubMed  Google Scholar 

  8. Ziessman HA, O’Malley J, Thrall J. Nuclear medicine: the requisites. 4th ed. Philadelphia: Elsevier Saunders; 2014. p. 66–97.

    Google Scholar 

  9. Atmaca A, Dogan S, Dagdelen S, Gurlek A, Bayraktar M, Adalar N. Symptomatic treatment of Graves hyperthyroidism with lithium in states of thionamide adverse reactions. Endocrinologist. 2004;14(6):317–20. doi:10.1097/01.ten.0000146399.37196.12.

    Article  Google Scholar 

  10. Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):723–33. doi:10.1016/j.beem.2009.06.002.

    Article  CAS  PubMed  Google Scholar 

  11. Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab. 2010;95(1):201–8. doi:10.1210/jc.2009-1655.

    Article  CAS  PubMed  Google Scholar 

  12. Turner JG, Brownlie BE, Rogers TG. Lithium as an adjunct to radioiodine therapy for thyrotoxicosis. Lancet. 1976;307(7960):2.

  13. Bogazzi F, Bartalena L, Campomori A, Brogioni S, Traino C, De Martino F, et al. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab. 2002;87(10):4490–5. doi:10.1210/jc.2002-020580.

    Article  CAS  PubMed  Google Scholar 

  14. Martin NM, Patel M, Nijher GM, Misra S, Murphy E, Meeran K. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease. Clin Endocrinol (Oxf). 2012;77(4):621–7. doi:10.1111/j.1365-2265.2012.04385.x.

    Article  CAS  Google Scholar 

  15. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593–646. doi:10.1089/thy.2010.0417.

    Article  PubMed  Google Scholar 

  16. Gayed I, Wendt J, Haynie T, Dhekne R, Moore W. Timing for repeated treatment of hyperthyroid disease with radioactive iodine after initial treatment failure. Clin Nucl Med. 2001;26(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  17. Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33(6):920–80. doi:10.1210/er.2012-1030.

    Article  CAS  PubMed  Google Scholar 

  18. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab. 2001;86(8):3488–93.

    CAS  PubMed  Google Scholar 

  19. Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid. 2002;12(5):399–405. doi:10.1089/105072502760043486.

    Article  CAS  PubMed  Google Scholar 

  20. Płazińska M, Królicki L, Bąk M. Lithium carbonate pre-treatment in 131-I therapy of hyperthyroidism. Nucl Med Rev Cent East Eur. 2011;14(1):3–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine and Molecular Imaging, Department of Radiation Sciences, University of the Witwatersrand, 7 York Road, Parktown, 2193, Johannesburg, South Africa

    Emmanuel NiiBoye Hammond & Mboyo-Di-Tamba Heben Willy Vangu

Authors
  1. Emmanuel NiiBoye Hammond
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mboyo-Di-Tamba Heben Willy Vangu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emmanuel NiiBoye Hammond.

Ethics declarations

Conflicts of interest

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Ethics clearance certificate number: M130846.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hammond, E.N., Vangu, MDT.H.W. Effect of adjuvant lithium on thyroxine (T4) concentration after radioactive iodine therapy. Eur J Nucl Med Mol Imaging 43, 1980–1987 (2016). https://doi.org/10.1007/s00259-016-3388-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-016-3388-3

Keywords

Search

Navigation